135307-49-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Methoxy-phenyl)-4-nitro-1H-imidazole is used as an intermediate in the synthesis of pharmaceuticals for its potential antimicrobial and antifungal properties. Its ability to inhibit the growth of certain microorganisms makes it a valuable compound in the development of new drugs to combat infections.
Used in Agricultural Industry:
In agriculture, 1-(4-Methoxy-phenyl)-4-nitro-1H-imidazole is utilized as an intermediate in the production of agricultural products, particularly those with antimicrobial and antifungal properties. Its application helps in the development of more effective treatments and preventive measures against various plant diseases caused by microorganisms.
Used in Research and Development:
1-(4-Methoxy-phenyl)-4-nitro-1H-imidazole is also used as a research compound for studying its potential biological activities and exploring its applications in medicine and agriculture. 1-(4-Methoxy-phenyl)-4-nitro-1H-imidazole's unique structure and properties make it an interesting subject for further investigation and development of novel therapeutic agents and agricultural solutions.

Upstream product

• 104-94-9 4-methoxy-aniline 
• 19182-81-1 1,4-dinitro-1H-imidazole 

Downstream Products

• 1185762-09-7 phenyl [1-(4-methoxyphenyl)-1H-imidazol-4-yl]carbamate 
• 158688-66-5 1-(4-methoxyphenyl)-1H-imidazol-4-amine 

Relevant academic research and scientific papers

IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE

Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I), (II), (III), or (IV), or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis

Nitroimidazoles are a well-known class of antibacterial and antiprotozoal drugs but in spite of the widespread clinical and veterinary use of these drugs, this family has been stigmatized in part due to associated genotoxicity problems. Here we report the synthesis, the anti-trypanosomal activity and a structure-activity relationship (SAR) study of a series of about fifty 1-aryl-4-nitro-1H-imidazoles, with an emphasis on selected in vivo active molecules. Compounds 4-nitro-1-{4-(trifluoromethoxy)phenyl}-1H-imidazole and 1-(3,4-dichlorophenyl)-4-nitro-1H-imidazole are curative in mouse models of both acute and chronic African trypanosomiasis when given orally at doses of 25-50 mg/kg for 4 days for the acute infection, and 50-100 mg/kg (bid) for 5 days in the chronic model. While both compounds are bacterial mutagens, activity is lost in strains lacking bacterial specific nitro-reductases. Mammalian nitro-reductases do not reduce nitroaromatic compounds with low redox potentials with same avidity as their bacterial counterparts and these compounds were shown to be devoid of genotoxicity in mammalian cells. Both compounds are promising leads for the treatment of human African trypanosomiasis (HAT or sleeping sickness), including the fatal stage 2 of the disease, for which new treatments are urgently needed.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds

Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure-activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic

Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles

Twelve N-aryl derivatives of 4-nitroimidazole, 2-methyl-4-nitroimidazole, 4-nitropyrazole or 3-nitro-1,2,4-triazole have been synthesized either by a degenerated ring transformation reaction of 1,4-dinitroimidazoles with 4-substituted anilines or by a condensation of fluoronitrobenzenes with salts prepared from C-nitro-1H-azoles and 1,8-diazabicyclo[5.4.0]-7-undecene. The Tuberculosis Antimicrobial Acquisition and Coordinating Facility has provided anti-mycobacterial data concerning inhibition activity of 12 compounds.